Disulfiram Exhibits Antibacterial Activity Against Borrelia Burgdorpheri in Two Studies In 2016 a researchers at Stanford University published research showing disulfiram, also known as Antabuse, as having antibacterial activity against Borrelia burgdorpheri, the bacteria that causes Lyme disease. The paper, Identification of New Drug Candidates Against Borrelia Burgdorferi Using High-Throughput Screening, identified disulfiram as its top candidate as having promise in treating Lyme disease and babesiosis infection. The in vitro study and others since then have shown that disulfiram is effective at killing both the actively replicating and the more quiescent persistent forms of Borrelia burgdorferi. In a paper published in May 2019 in the journal, Antibiotics, the author, Dr. Leigner, reported on three patients that he treated with disulfiram for Lyme disease. Each patient had required intensive antimicrobial therapy for control of the symptoms of chronic, relapsing, neurological Lyme disease and relapsing babesiosis. Each was able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram again. What is Disulfiram and Why is it Effective Against Lyme Disease? Disulfiram is a...